亚硝基苯甲酸盐 | 3876-38-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 亚硝基苯甲酸盐
• 英文名称: nitrosyl benzoate
• 英文别名: benzoyl nitrite；Benzoylnitrit；Salpetrigsaeure-benzoesaeure-anhydrid；Nitrosylbenzoat；nitroso benzoate
• CAS: 3876-38-8
• 化学式: C₇H₅NO₃
• 分子量: 151.122
• InChiKey: HIQQRJPIGOSGMT-UHFFFAOYSA-N

物化性质

• 沸点：
  38 °C(Press: 10.5 Torr)
• 密度：
  1.23±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  55.7
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2904209090

反应信息

• 作为反应物：
  描述：

  亚硝基苯甲酸盐 生成 苯甲酸酐
  参考文献：
  名称：

  Francesconi; Cialdea, Gazzetta Chimica Italiana, 1904, vol. 34 I, p. 445

  摘要：

  DOI：
• 作为产物：
  描述：

  silver benzoate 在 亚硝酰氯 作用下， 生成 亚硝基苯甲酸盐
  参考文献：
  名称：

  Francesconi; Cialdea, Gazzetta Chimica Italiana, 1904, vol. 34 I, p. 442

  摘要：

  DOI：
• 作为试剂：
  描述：

  2-甲氧基-4-甲基苯酚 在 亚硝基苯甲酸盐 作用下， 以 氯仿 为溶剂， 生成 2-甲氧基-4-甲基-6-硝基苯酚
  参考文献：
  名称：

  Koshi,K.; Shimizu,M., Chemical and pharmaceutical bulletin, 1968, vol. 16, p. 2343 - 2350

  摘要：

  DOI：

文献信息

• 2-Methylene-20-Methyl-19,24,25,26,27-Pentanor-Vitamin D Analogs
  申请人：DeLuca Hector F.

  公开号：US20090170822A1

  公开（公告）日：2009-07-02

  This invention discloses 2-methylene-20-methyl-19,24,25,26,27-pentanor-vitamin D analogs, and specifically 2-methylene-20-methyl-1α-hydroxy-19,24,25,26,27-pentanor-vitamin D 3 , and pharmaceutical uses therefore. This compound exhibits activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis as well as skin conditions such as wrinkles, slack skin, dry skin and insufficient sebum secretion. This compound also has little, if any, calcemic activity and therefore may be used to treat autoimmune disorders or inflammatory diseases in humans as well as renal osteodystrophy. This compound may also be used for the treatment or prevention of obesity.

  该发明披露了2-亚甲基-20-甲基-19,24,25,26,27-五缩戊-维生素D类似物，具体包括2-亚甲基-20-甲基-1α-羟基-19,24,25,26,27-五缩戊-维生素D3，以及其药用用途。该化合物表现出抑制未分化细胞增殖并诱导其分化为单核细胞的活性，从而表明其用作抗癌剂以及治疗银屑病等皮肤疾病以及皱纹、松弛皮肤、干燥皮肤和皮脂分泌不足等皮肤状况的用途。该化合物几乎没有钙代谢活性，因此可用于治疗人类的自身免疫性疾病或炎症性疾病以及肾性骨病。该化合物还可用于治疗或预防肥胖。
• [EN] 2-METHYLENE-20(21)-DEHYDRO-19,24,25,26,27,-PENTANOR-VITAMIN D ANALOGS<br/>[FR] ANALOGUES DE 2-MÉTHYLÈNE-20(21)-DÉSHYDRO-19,24,25,26,27-PENTANOR-VITAMINE D
  申请人：WISCONSIN ALUMNI I RES FOUNDATION

  公开号：WO2013012644A1

  公开（公告）日：2013-01-24

  This invention discloses 2-methylene-20(21)-dehydro-19,24,25,26, 27-pentanor-vitamin D analogs, and specifically 2-methylene-20(21)-dehydro-19,24,25,26,27-pentanor-1α-hydroxyvitamin D3, and pharmaceutical uses therefor. This compound exhibits relatively high transcription activity as well as pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis as well as skin conditions such as wrinkles, slack skin, dry skin and insufficient sebum secretion. This compound also shows lower activity in vivo on bone calcium mobilization and lower in vivo intestinal calcium transport activity as compared to the native hormone 1α,25-dihydroxyvitamin D3, and therefore may be used to treat autoimmune disorders or inflammatory diseases in humans as well as secondary hyperparathyroidism and renal osteodystrophy. This compound may also be used for the treatment or prevention of obesity.

  这项发明揭示了2-亚甲基-20(21)-去氢-19,24,25,26,27-五环-维生素D类似物，特别是2-亚甲基-20(21)-去氢-19,24,25,26,27-五环-1α-羟基维生素D3，以及其药用。该化合物显示出相对较高的转录活性，以及在阻止未分化细胞增殖和诱导它们分化成单核细胞方面的显著活性，因此表明可用作抗癌剂，用于治疗银屑病等皮肤疾病以及皱纹、松弛皮肤、干燥皮肤和皮脂分泌不足等皮肤状况。与天然激素1α,25-二羟基维生素D3相比，该化合物在体内对骨钙动员和肠钙转运活性较低，因此可用于治疗人类的自身免疫性疾病或炎症性疾病，以及继发性甲状旁腺功能亢进和肾性骨营养不良。该化合物还可用于肥胖的治疗或预防。
• 1alpha-Hydroxy-2-(3'-Hydroxypropylidene)-19-Nor-Vitamin D Compounds with a 1,1-Dimethylpropyl Side Chain
  申请人：DeLuca Hector F.

  公开号：US20070238703A1

  公开（公告）日：2007-10-11

  This invention discloses 1α-hydroxy-2-(3′-hydroxypropylidene)-19-nor-vitamin D compounds with a 1,1-dimethylpropyl side chain, and pharmaceutical uses therefor. These compounds exhibit pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis as well as skin conditions such as wrinkles, slack skin, dry skin and insufficient sebum secretion. These compounds also have little, if any, calcemic activity and therefore may be used to treat autoimmune disorders or inflammatory diseases in humans as well as renal osteodystrophy. These compounds may also be used for the treatment or prevention of obesity.

  该发明揭示了具有1,1-二甲基丙基侧链的1α-羟基-2-(3′-羟丙基亚甲基)-19-去氢维生素D化合物，并揭示了其在药物上的用途。这些化合物在抑制未分化细胞的增殖和诱导它们分化为单核细胞方面表现出显著的活性，从而表明其用作抗癌剂以及用于治疗银屑病等皮肤疾病以及皱纹、皮肤松弛、干燥皮肤和皮脂分泌不足等皮肤状况。这些化合物也几乎没有钙代谢活性，因此可以用于治疗人类的自身免疫性疾病或炎症性疾病以及肾性骨病。这些化合物还可以用于肥胖的治疗或预防。
• Synthesis of Nitroso- and Dinitroso Compounds by Reaction of Nitrosyl Benzoate and Dinitrosylterephthalate with Tetrasubstituted Alkenes
  作者：Brian Gowenlock、Thomas Sharpe

  DOI：10.1055/s-2006-942392

  日期：2006.6

  The reaction of nitrosyl benzoate with tetrasubstituted alkenes at 0 °C produces monomeric C-nitroso compounds in high yields. Similarly, the reaction of dinitrosyl terephthalate with 2,3-dimethylbut-2-ene affords a monomeric dinitroso compound. Extension to other nitrosyl esters gives similar high yields.

  苯甲酸亚硝基酯与四取代烯烃在 0 °C 下反应以高产率生成单体 C-亚硝基化合物。类似地，对苯二甲酸二亚硝基酯与 2,3-二甲基丁-2-烯反应得到单体二亚硝基化合物。扩展到其他亚硝基酯可得到类似的高产率。
• 2-Methylene-20(21)-Dehydro-19,24,25,26,27-Pentanor-Vitamin D Analogs
  申请人：DeLuca Hector F.

  公开号：US20130178449A1

  公开（公告）日：2013-07-11

  This invention discloses 2-methylene-20(21)-dehydro-19,24,25,26,27-pentanor-vitamin D analogs, and specifically 2-methylene-20(21)-dehydro-19,24,25,26,27-pentanor-1α-hydroxyvitamin D 3 , and pharmaceutical uses therefor. This compound exhibits relatively high transcription activity as well as pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis as well as skin conditions such as wrinkles, slack skin, dry skin and insufficient sebum secretion. This compound also shows lower activity in vivo on bone calcium mobilization and lower in vivo intestinal calcium transport activity as compared to the native hormone 1α,25-dihydroxyvitamin D 3 , and therefore may be used to treat autoimmune disorders or inflammatory diseases in humans as well as secondary hyperparathyroidism and renal osteodystrophy. This compound may also be used for the treatment or prevention of obesity.

  本发明揭示了2-亚甲基-20（21）-去氢-19,24,25,26,27-五环维生素D类似物，特别是2-亚甲基-20（21）-去氢-19,24,25,26,27-五环-1α-羟基维生素D3及其药物用途。该化合物表现出相对较高的转录活性以及显着的抑制未分化细胞增殖并诱导其分化成单核细胞的活性，因此可作为抗癌剂和治疗皮肤病如牛皮癣以及皮肤状况如皱纹、松弛皮肤、干燥皮肤和皮脂分泌不足的药物。该化合物在体内对骨钙动员和肠道钙转运活性的活性较天然激素1α,25-二羟基维生素D3低，因此可用于治疗人类的自身免疫性疾病或炎症性疾病，以及继发性甲状旁腺功能亢进和肾性骨营养不良。该化合物还可用于治疗或预防肥胖症。